Sanjiv J. Shah

Research interests

Publications

• Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2313917

• Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

  The Lancet · 2024 · https://doi.org/10.1016/s0140-6736(24)00469-0

• Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2407107

• Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

  Nature Medicine · 2023 · https://doi.org/10.1038/s41591-023-02526-x

• Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2306963

• Heart Failure With Preserved Ejection Fraction

  Journal of the American College of Cardiology · 2023 · 10.1016/j.jacc.2023.01.049

• Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2206286

• SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

  The Lancet · 2022 · 10.1016/s0140-6736(22)01429-5

• The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

  Nature Medicine · 2021 · 10.1038/s41591-021-01536-x

• ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2—Evidence Base and Standardized Methods of Imaging

  Circulation Cardiovascular Imaging · 2021 · https://doi.org/10.1161/hci.0000000000000029

• Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction

  Circulation · 2019 · https://doi.org/10.1161/circulationaha.119.044491

• ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging

  Journal of Nuclear Cardiology · 2019 · https://doi.org/10.1007/s12350-019-01760-6

• Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1908655

• Fully Automated Echocardiogram Interpretation in Clinical Practice

  Circulation · 2018 · 10.1161/circulationaha.118.034338

• Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1805689

• The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF

  JACC Heart Failure · 2018 · 10.1016/j.jchf.2018.05.018

• Endogenous Sex Hormones and Incident Cardiovascular Disease in Post-Menopausal Women

  Journal of the American College of Cardiology · 2018 · https://doi.org/10.1016/j.jacc.2018.01.083

• Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF

  European Heart Journal · 2018 · 10.1093/eurheartj/ehy531

• Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure])

  Circulation · 2017 · https://doi.org/10.1161/circulationaha.117.032094

• Genotype and Phenotype of Transthyretin Cardiac Amyloidosis

  Journal of the American College of Cardiology · 2016 · https://doi.org/10.1016/j.jacc.2016.03.596

• Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction

  Circulation · 2016 · 10.1161/circulationaha.116.021884

• Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population‐based study

  Hepatology · 2015 · https://doi.org/10.1002/hep.27869

• Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1510774

• Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction

  European Heart Journal · 2015 · 10.1093/eurheartj/ehv464

• Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone

  Circulation · 2015 · 10.1161/circulationaha.115.015884

• Spironolactone for Heart Failure with Preserved Ejection Fraction

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1313731

• Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial

  Circulation · 2014 · 10.1161/circulationaha.114.013255

• Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction

  Circulation · 2014 · 10.1161/circulationaha.114.010637

• Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction

  Circulation Heart Failure · 2013 · 10.1161/circheartfailure.113.000887

• Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial

  The Lancet · 2011 · 10.1016/s0140-6736(11)60982-3

• Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation

  European Respiratory Journal · 2009 · 10.1183/09031936.00072709

Current projects

No projects listed.